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Abstract
Background: The performance of the tuberculosis specific Interferon Gamma Release Assays (IGRAs) has not been
sufficiently documented in tuberculosis- and HIV-endemic settings. This study evaluated the sensitivity of the QuantiFERON
TB-Gold In-Tube (QFT-IT) in patients with culture confirmed pulmonary tuberculosis (PTB) in a TB- and HIV-endemic
population and the effect of HIV-infection and CD4 cell count on test performance.
Methodology/Principal Findings: 161 patients with sputum culture confirmed PTB were subjected to HIV- and QFT-IT
testing and measurement of CD4 cell count. The QFT-IT was positive in 74% (119/161; 95% CI: 67–81%). Sensitivity was
higher in HIV-negative (75/93) than in HIV-positive (44/68) patients (81% vs. 65%, p = 0.02) and increased with CD4 cell
count in HIV-positive patients (test for trend p= 0.03). 23 patients (14%) had an indeterminate result and this proportion
decreased with increasing CD4 cell count in HIV-positive patients (test for trend p= 0.03). Low CD4 cell count (,300 cells/ml)
did not account for all QFT-IT indeterminate nor all negative results. Sensitivity when excluding indeterminate results was
86% (95% CI: 81–92%) and did not differ between HIV-negative and HIV–positive patients (88 vs. 83%, p = 0.39).
Conclusions/Significance: Sensitivity of the QFT-IT for diagnosing active PTB infection was reasonable when excluding
indeterminate results and in HIV-negative patients. However, since the test missed more than 10% of patients, its potential
as a rule-out test for active TB disease is limited. Furthermore, test performance is impaired by low CD4 cell count in HIV-
positive patients and possibly by other factors as well in both HIV-positive and HIV-negative patients. This might limit the
potential of the test in populations where HIV-infection is prevalent.
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Introduction
There is a great demand throughout the world for new methods
for diagnosing both active and latent tuberculosis infection. New
methods for indirect tuberculosis (TB) diagnosis are now available,
including the Interferon Gamma Release Assays (IGRAs). IGRAs
are T-cell-based assays relying on the principle that sensitised T-
cells from a whole blood sample produce the cytokine Interferon-
gamma (IFN-c) when incubated with antigens specific for
M.tuberculosis (ESAT-6, CFP-10, TB-Antigen 7.7).
There are several potential uses of these tests. As the tests do not
distinguish between active and latent TB infection, their potential
for the diagnosis of active TB infection in TB endemic areas is
limited [1]. However, in evaluation of IGRA performance active
TB infection has commonly been used as a surrogate marker for
LTBI, while other studies have employed risk of exposure. Recent
prospective studies have shown that IGRAs might be more
accurate and thus have a higher predictive value in the diagnosis of
LTBI than does the conventional tuberculin skin test (TST) and a
role of IGRAs in ruling out TB disease in patients suspected of TB
has also been proposed [2–5]. The tests have already been taken
into use in clinical practice in several countries with low prevalence
of latent TB infection (LTBI).
HIV-infection increases the risk of progression from LTBI to
active TB disease and preventive treatment of LTBI in HIV-
positive individuals is increasingly recommended necessitating an
efficient test for diagnosing LTBI [6]. Although reports have
shown that IGRAs have a very impressive specificity for TB
infection, no golden standard is available for the diagnosis of LTBI
which makes sensitivity estimation difficult [7].
Two IGRAs are currently commercially available: the ELISA-
based QuantiFERON-TBH Gold In tube test (QFT-IT; Cellestis
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Limited, Australia) and the EliSPOT-based T-SPOT.TBH test
(Oxford Immunotec, Abingdon, United Kingdom). The QFT-IT
has recently received approval from the U.S. Food and Drugs
Administration [8] and recent guidelines are now recommending the
use of IGRAs for diagnosing LTBI as an alternative to the TST [7,9].
A recent review reported a pooled sensitivity of 70% for the QFT-IT
(95% CI: 65–78%) and 90% for the T-SPOT.TB (95% CI: 86–
93%)[9]. However, published studies in this area are highly variable
in respect to sample size, study population etc. Themajority of studies
of the QFT-IT have been carried out in high-income settings and not
in TB-andHIV-endemic countries where the burden is highest. Since
IGRAs rely on immune response, their performance may be
impaired in immunocompromised populations and in order to
determine the applicability of IGRAs in these areas, more studies
from such populations are needed. Previous studies in HIV-infected
populations have generally concluded that the QFT-IT is less
influenced by immune anergy than is the TST, but results are
diverging [5,7,10–16]. To our knowledge, only two studies have been
published on the performance of the QFT-IT in populations and
under conditions similar to ours. Raby et al [16] found an overall
sensitivity of the QFT-IT of 74% in patients with smear positive PTB
with lower sensitivity in 59 HIV-positive compared to 96 HIV-
negative patients (84 vs. 63%, p=0.03). This study also reported a
decrease in sensitivity with decreasing CD4 cell count in patients with
a CD4 cell count below 350 cells/ml as well as an association between
low CD4 cell count and a negative and indeterminate QFT-IT test
result. Tsiouris et al [14] found an overall sensitivity of 76% and,
though not significantly so, similarly found a lower sensitivity in 26
HIV-positive patients compared to 15 HIV-negative patients with
culture confirmed TB (65 vs. 73%, Fisher’s exact test p=0.73;
calculated by authors from crude data in article). They also found a
significantly lower mean level of IFN-c in HIV-positive patients
compared to HIV-negative patients (1.3 vs. 8.2 IU/ml, p=0.03).
Studies have reported similar results for the T-SPOT.TB test [17,18],
while others have reported that the T-SPOT.TB might be less
affected by immunodeficiency than is the QFT-IT [10,15,19].
The present study evaluated the sensitivity of the QFT-IT in
patients with culture confirmed pulmonaryTB disease (PTB) in a TB-
and HIV-endemic adult patient population in Tanzania and
evaluated the influence of HIV-status and CD4 cell count on test
performance.
Results
Patient characteristics
161 patients were included in the study. Demographic and
clinical characteristics of study participants are summarized in
Table 1. More men than women participated in the study (104 vs.
57, p,0.01) and the male to female rate was 1.82:1. A total of 68
patients (42%) were HIV-positive. Compared to men, a higher
proportion of women were HIV-positive (35 vs. 56%, p= 0.01).
Median lymphocyte count was 1626 cells/ml (inter-quartile range
1243–2224 cells/ ml) and median CD4 cell count was 377 cells/ml
(inter-quartile range 249–665 cells/ml).
QFT-IT results and sensitivity
Of the 161 patients included, 119 (74%, 95% CI: 67–81%) had
a positive, 19 (12%, 95% CI: 7–17%) had a negative and 23 (14%,
95% CI: 9–20%) had an indeterminate QFT-IT result (Table 2).
All 23 indeterminate results were due to an insufficient response to
both the PHA and the M.tb.-specific antigens. When excluding
indeterminate results sensitivity was 86% (95% CI: 81–92%).
Odds ratios for possible explanatory parameters for an
indeterminate QFT-IT result are listed in table 3. The following
parameters were not found to be associated with an indeterminate
QFT-IT result: body mass index (BMI), lymphocyte count above
the median of 1640 cells/ml, sputum microscopy smear grade of
3+. Factors associated with an indeterminate result were: CD4 cell
count below 300 cells/ml (by both univariate and multivariate
analysis), age above 33 years (by univariate analysis only) and male
sex (by multivariate analysis only). None of the mentioned
parameters were associated with a negative QFT-IT result and
no other differences were found when comparing medians and
proportions of these parameters between patients with positive,
negative and indeterminate results respectively.
Table 1. Demographic and clinical characteristics of patients according to HIV status.
Category Subcategory HIV-positive HIV-negative p-value*
(n =93) (n =68)
Male sex, n (%) 68 (73.1) 36 (52.9) 0.01
Age, median (IQR) 28 (23–37) 35 (29–42) ,0.01
BMI, median (range) 18.3 (13.2–23.8) 17.7 (12.0–27.6) 0.03
Lymphocyte count/ml, median (IQR) 1640 (1252–2263) 1510 (1230–2218) 0.80
CD4 cell count/ml, median (IQR) 519 (317–778) 272 (172–478) ,0.01
Smear grade{ 0, n (%) 18 (19) 17 (25) 0.39
1–9, n (%) 0 (0) 0 (0) n/a
1+, n (%) 6 (6) 11 (16) 0.05
2+, n (%) 22 (24) 11 (16) 0.25
3+, n (%) 42 (45) 28 (41) 0.61
Unknown, n (%) 5 (6) 1 (2)
*p-value for difference between HIV-negative and HIV–positive patients. IQR: Inter-quartile range.
{Smear grade by sputum microscopy: 0 (no acid fast bacilli [AFB] on smear), 1–9 (exact number of AFB per 100 fields), 1+ (10–99 AFB per 100 fields), 2+ (1–10 AFB per
field) and 3+ (more than 10 AFB per field).
doi:10.1371/journal.pone.0004220.t001
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Impact of HIV-status and CD4 cell count
BMI was significantly lower in HIV-positive than HIV–negative
patients (18.0 vs. 18.5, p= 0.03) as was median CD4 cell count
(272 vs. 519 cells/ml, p,0.01) (table 1).
Median antigen dependent and mitogen induced IFN-c
production for QFT-IT positive, negative and indeterminate
results for HIV-negative and HIV-positive patients respectively are
depicted in figure 1. No significant differences were found in
levels of IFN-c between HIV-positive and HIV-negative patients
when looking at each group of test results (p.0.05). However, as
shown in figure 2, overall median values of antigen dependent
IFN-c production were lower in HIV-positive than in HIV-
negative patients (p = 0.02). This was not the case for the mitogen
induced IFN-c production. No significant differences in IFN-c
were found between patients with a CD4 cell count above
compared to below 300 cells/ml.
Sensitivity of the QFT-IT was lower in HIV-positive than in
HIV–negative patients (65 [95% CI: 53–76%] vs. 81% [95% CI:
73–89%], p = 0.02) which was due to a larger proportion of QFT-
IT indeterminate results among HIV-positive patients compared
to HIV-negative patients (22 vs. 9%, p= 0.02). When excluding
indeterminate results, sensitivity increased to 83% in HIV-positive
(44/53; 95% CI: 73–93%) and to 88% (75/85; 95% CI: 79–94%)
in HIV-negative patients and no difference was observed in
sensitivity between the HIV-positive and HIV–negative patients
(p = 0.39). Furthermore, when excluding QFT-IT indeterminate
results no significant difference was found in median antigen
dependent IFN-c production (p= 0.20).
A positive trend of sensitivity with increasing CD4 cell count
was observed for HIV-positive patients when stratifying CD4 cell
counts into groups of ,100, 100–200, 200–300, 300–400, 400–
500, .500 (p= 0.03). We found a similar inverse trend with
increasing proportion of indeterminate results with decreasing
CD4 cell count (p = 0.03). When excluding indeterminate results
no trend was observed for sensitivity and CD4 cell count (p = 0.44)
(Figure 3). These findings were observed both when dividing
CD4 cell counts into groups of pentiles and when dividing them
into groups of hundreds. In HIV-positive patients, QFT-IT
sensitivity was significantly lower in patients with CD4 cell count
below compared to above 300 cells/ml (52 vs. 85%, p= 0.01). This
was not the case for HIV-negative patients (90 vs. 78%, p= 0.35).
Discussion
This study evaluated the performance of the QFT-IT test in a
TB- and HIV-endemic population. A sputum culture positive for
M.tb. was used as standard for present TB infection and the
influence of HIV-infection and CD4 cell count on test perfor-
mance was investigated as were risk factors for a negative or
indeterminate QFT-IT result.
The observed sensitivity of 74% when including indeterminate
results is in the lower end of the spectre for previously reported
studies of QFT-IT sensitivity [7,14,16,20–22]. Nevertheless,
studies carried out in similar populations, Tsiouris et al [14] and
Raby et al [16], reported sensitivities of 74% and 76%
respectively, which is comparable to our findings. In HIV-negative
patients we found a sensitivity of 81% which is fully comparable to
previous studies in high income populations [7,20,21,23].
We have shown that test performance is impaired in HIV-
positive patients, as has also been suggested by previous studies:
While Rangaka et al [10] found no influence of HIV-status on test
performance for diagnosing LTBI, other studies have shown that
HIV-status and immune deficiency does in fact affect test
performance for the diagnosis of both LTBI and active TB
Table 2. QuantiFERON-TBH Gold In-tube results for all study participants and according to HIV status.
QFT-IT result All HIV-negative HIV-positive p-value*
(n=161) (n=93) (n =63)
Positive, n (%) 119 (74) 75 (81) 44 (65) 0.02
Negative, n (%) 19 (12) 10 (11) 9 (13) 0.63
Indeterminate, n (%) 23 (14) 8 (9) 15 (22) 0.02
QFT-IT: QuantiFERON-TBH Gold In-tube test.
*p-value for difference between HIV-negative and HIV–positive patients.
doi:10.1371/journal.pone.0004220.t002
Table 3. Association of risk factors with an indeterminate QuantiFERON-TBH Gold In-tube result.
Parameter n Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Male sex 104 2.96 (0.96–9.18) 0.06 3.25 (1.00–10.49) 0.05
Age.33 years 71 2.75 (1.09–6.91) 0.03 2.51 (0.56–11.28) 0.23
BMI ,18.5 98 0.81 (0.33–1.98) 0.64 0.68 (0.26–1.77) 0.43
CD4 cell count ,300 cells/ml 62 2.83 (1.14–7.00) 0.02 3.41 (1.25–9.29) 0.02
Lymphocyte count ,1640 cells/ml 83 1.42 (0.58–3.45) 0.44 1.21 (0.43–2.92) 0.81
3+ AFB by sputum smear microscopy 70 1.86 (0.61–5.67) 0.27 1.57 (0.57–4.27) 0.38
A total of 23 out of 161 patients (14%) had a QFT-IT indeterminate result. No differences were found in OR when comparing QFT-IT positive and negative patients. OR:
Odds Ratio. CI: Confidence interval. BMI: Body Mass Index. Age of 33 years and lymphocyte count of 1640 cells/ml represents medians for all patients. 3+ AFB by sputum
smear microscopy: More than 10 acid fast bacilli (AFB) per field.
doi:10.1371/journal.pone.0004220.t003
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infection [5,7,10–16]. Raby et al [16] reported a decrease in
sensitivity of 21 percentage points in HIV-positive compared to
HIV-negative patients when including indeterminate results and
other studies of test performance in HIV-positive patients have
reported similar findings [18].
Since the cut-off point of the test (0.35 IU/ml) is very low
compared to the rather wide range of IFN-c production (assay
sensitivity up to 10 IU/ml), the absolute IFN-c values might be
difficult to interpret compared to the results deducted from the
algorithm, which merely considers whether a data point lies above
or below the cut-off value. They may, however, be useful in
illustrating some inherent properties of the test. Our data
demonstrate a lower median antigen dependent IFN-c production
in HIV-positive compared to HIV-negative patients. This
difference was not observed when comparing HIV-positive and
HIV-negative patients within the isolated result groups (positive,
negative and indeterminate respectively) and we found no
difference in median IFN-c production between patients with
CD4 cell count above and below 300 cells/ml. This might however
be due to lack of power. Although one of the advantages of the
QFT-IT often emphasized is the dichotomous test outcome, the
cut-off is still a matter of debate and research [24,25]. In our study,
two patients with a negative and one patient with an indeterminate
QFT-IT result had an antigen dependent IFN-c response very
Figure 1. Antigen dependent and mitogen induced absolute IFN-c levels by QuantiFERON-TBH Gold In-tube test result in HIV-
negative and HIV-positive patients respectively. Horisontal lines represent medians. Dotted lines represent the applied cut-off values as
recommended by the manufacturer: 0.35 IU/ml for antigen (ESAT-6, CFP-10, TB7.7) dependent IFN-c production and 0.50 IU/ml for mitogen (PHA)
induced IFN-c production respectively. The assay is not able to quantify values above 10 IU/ml why values above this limit were assigned the value
10 IU/ml. No significant differences in median levels between HIV-positive and HIV-negative were observed.
doi:10.1371/journal.pone.0004220.g001
Figure 2. Antigen dependent and mitogen induced absolute IFN-c levels by HIV-status and CD4 cell count group. Horisontal lines
represent medians with interquartile range. Dotted lines represent the applied cut-off values as recommended by the manufacturer: 0.35 IU/ml for
antigen (ESAT-6, CFP-10, TB7.7) dependent IFN-c production and 0.50 IU/ml for mitogen (PHA) induced IFN-c production respectively. The assay is
not able to quantify values above 10 IU/ml why values above this limit were assigned the value 10 IU/ml.
doi:10.1371/journal.pone.0004220.g002
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close to the cut-off value of 0.35 IU/ml (0.32, 0.34 and 0.34 IU/
ml respectively; data not shown).
Similar to the findings of Raby et al [16], we have demonstrated a
clear trend of decreasing sensitivity with decreasing CD4 cell count
in HIV-positive patients. Other studies have also found an
association between low CD4 cell count and low QFT-IT sensitivity
and/or high levels of indeterminate results in HIV-positive patients
[12–14,18,19,26], while other studies do not reproduce this finding
[5,10,27]. The division of CD4 cell count into ranges of hundreds
was chosen due to the straightforward clinical interpretation, but
this also skews the data somewhat as the number of patients in each
group is far from equal. Nevertheless, the trend was also found when
dividing CD4 cell count groups into percentiles with equal numbers
of patients in each group. In our study, the observed trend was
mediated by an increasing number of indeterminate results with low
CD4 cell count, since, when excluding indeterminate result, the
trend could not be reproduced. Also, when excluding indeterminate
result, we found no difference in sensitivity between HIV-negative
and HIV–positive patients and no difference in median level of
antigen dependent IFN-c production. Nevertheless, a low CD4 cell
count was not associated with indeterminate results in HIV-negative
patients which might suggest that anergy of HIV-infected cells in
HIV-positive patients makes adequate cytokine production more
dependent on absolute cell numbers.
Although we found a larger proportion of indeterminate results
(23/161= 14%) than the majority of previously published studies,
the proportion is similar to the proportion reported from studies
from similar populations: Tsiouris et al [14] found 23 out of 154
(15%) results to be indeterminate while Raby et al [16] found 16
out of 112 (14%) results to be indeterminate. Similar to the
findings of these studies, the majority of the indeterminate results
was found in HIV-positive patients and could be explained by a
low CD4 cell count.
The PHA positive control is a marker of immune mediated
anergy and serves to eliminate a large proportion of otherwise false
negative test results by classifying them instead as ‘‘indeterminate’’.
From a clinician’s point of view, the sensitivity should address the
risk that the test is false negative, i.e. the sensitivity for a valid
QFT-IT response. This is expressed by the sensitivity when
excluding indeterminate results. In our study the sensitivity when
excluding indeterminate results was markedly better (86%),
especially in HIV-positive patients: sensitivity increased from 65
to 83% in HIV-positive and from 81 to 88% in HIV-negative
patients with no difference in sensitivity between the two groups
(p = 0.45). Similar improvements in sensitivity when excluding
indeterminate results have been found for HIV-positive patients in
other studies [14,16]. Although reporting an improvement from
63 to 78%, Raby et al [16] still found a lower sensitivity in HIV-
positive than HIV-negative patients after correcting for indeter-
minate results (chi-square test, p = 0.01; calculated by authors from
crude data in article). The study also found a significant
association between a negative QFT-IT result and low CD4 cell
count which may explain this finding. However, this particular
association was not reproduced by our data.
All indeterminate results were due to an inadequate IFN-c
production in response to both the PHA positive control and the
M.tb.-specific antigens. While the majority of these results were
related to a lowCD4 cell count as illustrated by the trend in Figure 3,
indeterminate results also occurred in 7 out of 73 (10%) HIV-
negative patients with a CD4 cell count above 300 cells/ml (data not
shown). Other factors yet unidentified may account for these results.
By multivariate analysis we found that male patients had a greater
risk compared to females of having an indeterminate QFT-IT result
(table 3). This is in contrast to the findings of Chee et al. [23] and the
findings may reflect behavioural or social differences between the
sexes rather than physiological properties. Also, we found that
patients aged 33 or older were more likely to have an indeterminate
results, but this was by univariate analysis only.
Even when excluding the indeterminate results, the QFT-IT still
missed 19 (12%) of patients with culture confirmed TB disease.
Previous studies have described a connection between a false
negative QFT-IT result and age above 60 years, female sex and
CD4 cell count [10,16,23]. Our data did not reproduce these
findings. Also, a connection between false negative results and
advanced cavitary disease has been suggested, although data on
the subject has not been consistent [22,28–33]. Our results did not
support this suggestion as patients with negative or indeterminate
QFT-IT results did not have higher bacterial loads by sputum
microscopy, which has been shown to be associated with cavitary
disease [34,35]. An alternative explanation for the false negative
results might be antigen specific anergy of sensitised T-cells or
homing of the T-cells to the site of infection; phenomenons which
Figure 3. Influence of CD4 cell count on performance of the QuantiFERON-TBH Gold In-tube test in HIV-positive patients. For HIV-
positive patients the % of indeterminate and positive test responders respectively was grouped by the individual number of CD4 cells/ml. P-values are
for Cochrane-Armitage test for trend. A similar relationship was not found in HIV-negative patients. The number of patients in each CD4 cell group
was: 0–99: 5, 100–199: 17, 200–299: 20, 300–399:6, 400–499:6, .500:14. QFT-IT: QuantiFERON-TBH Gold In-tube test.
doi:10.1371/journal.pone.0004220.g003
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have previously been described in connection with both PPD
antigen tests and a similar Interferon Gamma Release Assay (the
T-SPOT.TB) [36,37].
As previously mentioned, potential uses of the IGRAs in TB-
and HIV-endemic settings include exclusion of TB disease in
patients suspected of TB disease as well as screening of risk
populations, e.g. HIV-positive persons, for LTBI allowing for
targeted preventive therapy [3]. Immunoassays do indeed seem to
be promising candidates for replacement of the TST in the
diagnosis of LTBI, however we and others have shown that to
some extent test performance is impaired in HIV-infected patients
with low CD4 cell counts. Furthermore, studies in these regions
have found that up to 50% of the adult population is IGRA
positive [10], but not necessarily suffering from active TB, possibly
compromising specificity for diagnosing and excluding active TB
infection. This issue was not the focus of our study but is currently
being addressed in a community study in the same area. A recent
study suggests that IGRAs may be useful in children where the risk
of exposure due to young age is much lower [38].
Measures might be taken in order to improve the performance
of immunoassays: re-evaluation of the recommended cut-off value
might prove beneficial [24,25] as might the exploration of
alternative biomarkers for TB diagnosis [39]. Considering the
financial and technical requirements of the test and the reduced
specificity and sensitivity for active TB infection in areas where
LTBI and HIV-infection is prevalent, cost-effectiveness is most
likely low in the areas with the highest burden of TB infection.
Nevertheless immunoassays have plenty of potential for improve-
ment and further studies are needed to investigate how to optimise
IGRA performance in TB- and HIV-endemic populations.
Materials and Methods
Setting, patient recruitment and eligibility
The study was conducted in Mwanza City, the second largest
city in Tanzania. The TB incidence and HIV prevalence among
the adult population (15–49 years) was estimated to be 342 per
100 000 and 6.5% respectively (2005) [40]. HIV prevalence in
active TB cases was estimated to be 29% [40], however a recent
study conducted in Mwanza, Tanzania found that 44% of the
sputum smear positive patients were HIV-infected [41].
The study was conducted from April through December 2006
as a sub-study within the framework of two on-going randomised
nutritional supplementation trials in TB patients. In Tanzania all
patients presenting to a public health facility with TB-suspicious
disease are referred to the National Tuberculosis and Leprosy
Programme of Tanzania (NTLP) for diagnosis and treatment free
of charge. PTB-diagnosis is based primarily on sputum smear
microscopy or clinical criteria as by WHO recommendations and
definitions [42]. PTB patients were recruited in four facilities (two
hospitals and two health centers) in Mwanza City through the
NTLP. Apart from inclusion in the NTLP, inclusion criteria were:
consent to donate blood for the relevant tests as well as claiming it
likely that they would remain in the study are during the entire
study period. Exclusion criteria were: age below 15 years,
pregnancy or lactation and/or presence of serious co-morbidity.
Patients where no valid HIV result could be obtained were also
excluded from the study. For this sub-study only patients with a
positive sputum culture for M.tb. were included.
Study assessments and measurements
i) Sputum microscopy and culture. Routine sputum
microscopy (Ziehl-Neelsen sputum smear staining technique) for
acid fast bacilli (AFB) was performed as part of the NTLP of
Tanzania. Smears were graded according to the IUATLD
standard [43] as follows: 0 (no AFB on smear), 1–9 (exact
number of AFB per 100 fields), 1+ (10–99 AFB per 100 fields), 2+
(1–10 AFB per field) and 3+ (more than 10 AFB per field). Sputum
smear grade was based on the smear with the largest amount of
AFB found. Upon inclusion, an additional sputum sample was
collected for culture for M.tb. performed on egg-based Lowenstein-
Jensen solid media at the Zonal Tuberculosis Reference
Laboratory at Bugando Medical Centre, Mwanza.
ii) HIV testing, lymphocyte and CD4 counts, clinical
parameters. HIV testing was performed in duplicates using
rapid tests Determine HIV 1/2 (Inverness Medical Innovations,
Inc., Delaware, U.S.A.) and Capillus HIV-1/HIV-2 (Trinity
Biotech Plc., Wicklow Ireland). Any indeterminate results were
repeated and confirmed using ELISA – Organon Uniform II
(Organon Teknia, the Netherlands). Lymphocyte count was
obtained by direct microscopy of Leishman-stained blood
smears. CD4 cell counts were obtained using the Partec FACS
(Partec GmbH,. Mu¨nster, Germany). Body mass index (BMI) was
calculated as weight (kg) divided by height (m) squared.
iii) QuantiFERON-TBH Gold In-Tube (QFT-IT)
test. Blood was collected from study participants in
heparinized tubes (Lithium heparinized plasmacontainers 4 ml,
BD VacutainerH, BD Denmark, Brøndby, DK) in each of the four
main study centres and transported to the study laboratory within
8 hours. One ml of blood was transferred to each of the 3 QFT-IT
test blood collection tubes pre-coated with the TB-specific
antigens, a phytohemagglutinin (PHA) positive control (Mitogen)
and a negative (Nil) control tube respectively. The samples were
then shaken in order to ensure proper mixing of blood with
contents and incubated upright at temperature 37uC for 20–
24 hours. They were centrifuged at 3,0006g for 10 minutes and
plasma was harvested and collected in NuncH cryotubes (Nunc,
Roskilde, Denmark) and stored frozen at 280uC. Plasma samples
were transported on dry ice from Tanzania to the Department of
Infectious Diseases at Copenhagen University Hospital, Hvidovre,
Denmark, where ELISA testing was performed. Samples were
tested in random order and laboratory personnel were blinded
with regard to sputum-, culture- and HIV-status of the patients.
Samples from up to 28 patients were ELISA tested at a time and
the ELISA was performed in accordance with the instructions of
the manufacturer (www.cellestis.com). ELISA readings were
transferred to the QFT-Gold v.2.50 Software giving final QFT-
IT test results as calculated by manufacturer’s recommendations.
The QFT-IT result was graded as positive if the IFN-c in plasma
of the antigen-stimulated blood was .0.35 IU/ml after
subtracting the cytokine concentration of unstimulated plasma
and the stimulation index (IFN–c concentration in plasma of
antigen stimulated blood divided by IFN–c concentration of
unstimulated blood) was $1.25 regardless of the mitogen
stimulated IFN–c response. Responses were graded as negative
if the antigen-specific response was ,0.35 IU/ml and the mitogen
stimulated IFN-c response was $0.5 IU/ml. Responses were
indeterminate if either the IFN-c response in the unstimulated
sample was $8 IU/ml regardless of the antigen-specific and the
mitogen-stimulated responses or if both the antigen-specific
response was ,0.35 IU/ml and the mitogen-stimulated IFN-c
response was #0,5 IU/ml.
iv) Statistical analysis. Data were entered and analyzed
using SAS 9.1 for Windows (SAS Institute Inc., Cary, NC, USA).
Sensitivity estimates were calculated using only patients with a
positive sputum culture for M.tb. Analyses were done two-sided,
confidence intervals (CI) were 95% and a result was considered
significant when the p-value was below 0.05. Continuous variables
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were tested for normality using the Shapiro-Wilk test and
compared using the Student’s t-test if normally distributed;
otherwise the Mann-Whitney test was applied. The Chi-square
test was applied for comparing categorical variables unless one of
the categories had less than 20 observations in which case the
Fisher’s exact test was applied. Test for trend was done using the
Cochrane-Armitage test and correlation calculations were done
using the Spearman non-parametric method. Odds ratio (OR)
analysis for risk factors was performed by both uni- and
multivariate analysis.
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